These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15479215)

  • 1. ACE inhibitors and cardiovascular protection in diabetes.
    Donnelly R
    Diabetes Obes Metab; 2004 Nov; 6(6):399-401. PubMed ID: 15479215
    [No Abstract]   [Full Text] [Related]  

  • 2. [Need of tight blood pressure control in type 2 diabetes. The intervention study ADVANCE gives clear information].
    Nilsson PM
    Lakartidningen; 2007 Oct 17-23; 104(42):3028-9. PubMed ID: 17985709
    [No Abstract]   [Full Text] [Related]  

  • 3. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renin angiotensin system and cardiovascular disease: hope or hype?
    Williams B
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):142-6. PubMed ID: 11967805
    [No Abstract]   [Full Text] [Related]  

  • 5. The emerging role of ACE inhibitors in diabetes: from theory to therapeutic management.
    Yudkin JS
    J Diabetes Complications; 1996; 10(3):129-32. PubMed ID: 8807456
    [No Abstract]   [Full Text] [Related]  

  • 6. [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"].
    Seufert J
    Dtsch Med Wochenschr; 2008 May; 133(20):1068-70. PubMed ID: 18461525
    [No Abstract]   [Full Text] [Related]  

  • 7. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 8. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE inhibitors reduce heart-related death in type 2 diabetics.
    Health News; 2004 Oct; 10(10):15. PubMed ID: 15584126
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin converting enzyme inhibitors in the treatment of diabetes].
    Smahelová A
    Vnitr Lek; 2003 Dec; 49(12):948-51. PubMed ID: 15040161
    [No Abstract]   [Full Text] [Related]  

  • 13. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late-diabetic complications.
    Gaede PH
    Dan Med Bull; 2006 Aug; 53(3):258-84. PubMed ID: 17092449
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of treatment of hypertension on cardiovascular outcome in type 2 diabetes.
    Migdalis IN
    Res Commun Mol Pathol Pharmacol; 2006; 119(1-6):105-14. PubMed ID: 17974100
    [No Abstract]   [Full Text] [Related]  

  • 16. French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors.
    Marant C; Romon I; Fosse S; Weill A; Simon D; Eschwège E; Varroud-Vial M; Fagot-Campagna A
    Diabetes Metab; 2008 Feb; 34(1):38-45. PubMed ID: 18068386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 18. HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.
    Marshall SM
    Diabet Med; 2000 Sep; 17 Suppl 2():9-10. PubMed ID: 11048826
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.
    Campbell HM; Boardman KD; Dodd MA; Raisch DW
    Ann Pharmacother; 2007 Jul; 41(7):1101-10. PubMed ID: 17609233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.
    Skyler JS; Bergenstal R; Bonow RO; Buse J; Deedwania P; Gale EA; Howard BV; Kirkman MS; Kosiborod M; Reaven P; Sherwin RS; ; ;
    J Am Coll Cardiol; 2009 Jan; 53(3):298-304. PubMed ID: 19147051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.